Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso

This study has been completed.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID) Identifier:
First received: November 19, 2009
Last updated: June 5, 2014
Last verified: February 2012